3 hours ago
ASH 2024: Kite Pharma's global head discusses the progress of the CAR-T field, Arcellx's BCMA data, cures in CD19, autoimmune, and future targets
Cindy Perettie describes why she took the head job at Kite a little over a year ago, long-term CD19 data, tonight's BCMA update, Kite's...
4 hours ago
ASH 2024: Arcellx CEO Rami Elghandour discusses a data update of the iMMagine-1 Study for the company's BCMA CAR-T
The data showed a 62% CR/sCR at a median follow-up of 9.5 months. He discusses the patient population, next steps, and the work that...
7 hours ago
ASH 2024: Beam's CEO John Evans on the company's based editing sickle cell data, and preclinical data on a next generation product meant to broaden the potential patient population
He describes clinical data presented at ASH for BEAM-101 and how he believes it stacks up against competition that is on the market....
.png){kind=logo}
